Endo’s Par Wins Block on QuVa Competing Aseptic Products

March 19, 2018, 8:02 PM

QuVa Pharma Inc. must stop selling aseptic products that directly compete with Par Pharmaceutical Inc.'s Vasostrict until trade secret litigation between the two companies ends.

Par is likely to succeed on its claim that QuVa, a company formed by former Par employees, misappropriated Par’s manufacturing trade secrets for its sterile products, including Vasostrict, Judge Brian R. Martinotti of the U.S. District Court for the District of New Jersey said in a March 1 opinion made public March 16. Vasostrict (vasopressin) is an intravenous product indicated to increase blood pressure in adults with septic shock.

The injunction means QuVa can’t sell ...

To read the full article log in.

Learn more about a Bloomberg Law subscription.